Role of IL-12 in the induction and potentiation of IFN-γ in response to bacillus Calmette-Guerin

Journal of Immunology

Volumn 163, Issue 8, 1999, Pages 4246-4252

  O'Donnell, Michael A ^a   Luo, Yi ^a   Chen, Xiaohong ^a   Szilvasi, Akos ^a   Hunter, Sharon E ^b   Clinton, Steven K ^c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b PFIZER INC   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 2; NEUTRALIZING ANTIBODY; RECOMBINANT INTERLEUKIN 12;

ANIMAL CELL; ARTICLE; BLADDER CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; INTERFERON INDUCTION; INTRAVESICAL DRUG ADMINISTRATION; KINETICS; MOUSE; MYCOBACTERIUM BOVIS; PRIORITY JOURNAL;

EID: 0032844738     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Herr, H. W., V. P. Laudone, R. A. Badalament, H. F. Oettgen, P. C. Sogani, B. D. Freedman, M. R. Melamed, and W. F. Whitmore, Jr. 1988. Bacillus Calmette-Guérin therapy alters the progression of superficial bladder cancer. J. Clin. Oncol. 6:1450.
2. Lamm, D. L., B. A. Blumenstein, E. D. Crawford, J. E. Montie, P. Scardino, H. B. Grossman, T. H. Stanisic, J. A. Smith, Jr., J. Sullivan, M. F. Sarosdy, et al. 1991. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder. N. Engl. J. Med. 325:1205.
3. Martinez-Pineiro, J. A., J. Jimenez Leon, L. Martinez-Pineiro, Jr., L. Fiter, J. A. Mosteiro, J. Navarro, M. J. Garcia Matres, and P. Carcamo. 1990. Bacillus Calmette-Guérin versus doxombicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer. J. Urol. 143:502.
4. Ratliff, T. L. 1992. Role of the immune response in BCG for bladder cancer. Eur. Urol. 21(Suppl.)2:17.
5. Bohle, A., C. Nowc, A. J. Ulmer, J. Musehold, J. Gerdes, A. G. Hofstetter, and H. D. Flad. 1990. Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy. J. Urol. 144:59.
6. de Reijke, T. M., E. C. de Boer, K. H. Kurth, and D. H. Schamhart. 1996. Urinary cytokines during intravesical bacillus Calmetle-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value. J. Urol. 155:477.
7. Esuvaranathan, K., A. B. Alexandroff, M. McIntyre, A. M. Jackson, S. Prescott, G. D. Chisholm, and K. James. 1995. Interleukin-6 production by bladder tumors is upregulated by BCG immunotherapy. J. Urol. 154:572.
8. Prescott, S., K. James, T. B. Hargreave, G. D. Chisholm, and J. F. Smyth. 1990. Radio-immunoassay detection of interferon-γ in urine after intravesical Evans BCG therapy. J. Urol. 144:1248.
9. Thalmann, G. N., B. Dewald, M. Baggiolini, and U. E. Studer. 1996. Interleukin-8 expression in the urine after BCG therapy: a potential predictor of tumor recurrence and progression. J. Urol. 155:34A (abstr.).
10. O'Donnell, M. A., X. Chen, and W. C. DeWolf. 1996. Maturation of the cytokine immune response to BCG in the bladder: implications for treatment schedules. J. Urol. 155:1030A (abstr.).
11. Alexandroff, A. B., A. M. Jackson, A. Skibinska, and K. James. 1996. Production of IL-5, a classical TH2 cytokine, following bacillus Calmette Guérin immunotherapy of bladder cancer. Int. J. Oncol. 9:179.
12. Huygen, K., D. Abramowicz, P. Vandenbussche, F. Jacobs, J. De Bruyn, A. Kentos, A. Drowart, J. P. Van Vooren, and M. Goldman. 1992. Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice. Infect. Immun. 60:2880.
13. de Kossodo, S., R. Moore, S. Gschmeissner, N. East, C. Upton, and F. R. Balkwill. 1995. Changes in endogenous cytokines, adhesion molecules and platelets during cytokine-induced tumour necrosis. Br. J. Cancer 72:1165.
14. Hawkyard, S. J., A. M. Jackson, K. James, S. Prescott, J. F. Smyth, and G. D. Chisholm. 1992. The inhibitory effects of interferon γ on the growth of bladder cancer cells. J. Urol. 147:1399.
15. Jackson, A. M., A. B. Alexandrov, S. Prescott, K. James, and G. D. Chisholm. 1992. Expression of adhesion molecules by bladder cancer cells: modulation by interferon-γ and tumor necrosis factor-α. J. Urol. 148:1583.
16. + human marrow cells is induced by interferon γ and tumor necrosis factor α and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85:3183.
17. Pandita, R., E. Pocsik, and B. B. Aggarwal. 1992. Interferon-γ induces cell surface expression for both types of tumor necrosis factor receptors. FEBS Lett. 312:87.
18. Hawkyard, S. J., A. M. Jackson, S. Prescott, K. James, and G. D. Chisholm. 1993. The effect of recombinant cytokines on bladder cancer cells in vitro. J. Urol. 150:514.
19. Campbell, S. C., K. Tanabe, J. P. Alexander, M. Edinger, R. R. Tubbs, and E. A. Klein. 1994. Intercellular adhesion molecule-1 expression by bladder cancer cells: functional eifects. J. Urol. 151:1385.
20. Lamm, D. L. 1992. Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. North Am. 19:573.
21. + T cells to enhance priming for interferon-γ production and diminishes interleukin 4 inhibition of such priming. Proc. Natl. Acad. Sri. USA 90:10188.
22. + T cell subsets and induces early resistance to Leishmania major in mice. J. Exp. Med. 178:567.
23. Chan, S. H., B. Perussia, J. W. Gupta, M. M. P. Kobayashi, H. A. Young, S. F. Wolf, D. Young, S. C. Clark, and G. Trinchieri. 1991. Induction of IFN-γ production by NK cell stimulatory factor (NKSF): characterization of the responder cells and synergy with other inducers. J. Exp. Med. 173:869.
24. Kobayashi, M., L. Fitz, M. Ryan, R. M. Hewick, S. C. Clark, S. Chan, R. Loudon, F. Scherman, B. Perussia, and G. Trinchieri. 1989. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med. 170:827.
25. Trinchieri, G. 1995. Interleukin-12: a proinflammatory cytokine with immuno-regulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu. Rev. Immunol. 13:251.
26. Manetti, R., P. Parronchi, M. G. Giudizi, M. P. Piccinni, E. Maggi, G. Trinchieri, and S. Romagnani. 1993. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J. Exp. Med. 177:1199.
27. Fearon, D. T., and R. M. Locksley. 1996. The instructive role of innate immunity in the acquired immune response. Science 27:50.
28. Stover, C. K., V. F. de la Cruz, T. R. Fuerst, J. E. Burlein, L. A. Benson, L. T. Bennett, G. P. Bansal, J. F. Young, M. H. Lee, G. F. Hatfull, et al. 1991. New use of BCG for recombinant vaccines. Nature 351:456.
29. O'Donnell, M. A., A. Aldovini, R. B. Duda, H. Yang, A. Szilvasi, R. A. Young, and W. C. DeWolf. 1994. Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances γ interferon production by splenocytes. Infect. Immun. 62:2508.
30. van der Meijden, A. P., F. M. Debruyne, P. A. Steerenberg, and W. H. de Jong. 1989. Aspects of non-specific immunotherapy with BCG in superficial bladder cancer: an overview. Prog. Clin. Biol. Res. 310:11.
31. O'Donnell, M. A., and W. C. DeWolf. 1995. Bacillus Calmette-Guérin immunotherapy for superficial bladder cancer: new prospects for an old warhorse. Surg. Oncol. Clin. North Am. 4:189.
32. Ratliff, T. L., D. Gillen, and W. J. Catalona. 1987. Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J. Urol. 137: 155.
33. Ratliff, T. L., J. K. Ritchey, J. J. Yuan, G. L. Andriole, and W. J. Catalona. 1993. T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol. 150:1018.
34. Fleischmann, J. D., Z. Toossi, J. J. Ellner, D. B. Wentworth, T. L. Ratliff, and A. L. Imbembo. 1989. Urinary interleukins in patients receiving intravesical Bacillus Calmette-Guérin therapy for superficial bladder cancer. Cancer 64:1447.
35. Gately, M. K., B. B. Desai, A. G. Wolitzky, P. M. Quinn, C. M. Dwyer, F. J. Podlaski, P. C. Familletti, F. Sinigaglia, R. Chizzonite, U. Gubler, et al. 1991. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J. Immunol. 147:874.
36. + T lymphocytes and NK cells. J. Immunol. 149:3495.
37. Mendez-Samperio, P., A. Trejo-Echeverria, and H. Ayala-Verdin. 1998. Regulation of interleukin-12 production in human cells stimulated with Mycobacterium bovis BCG. Cell. Immunol. 189:25.
38. Poppas, D. P., C. P. Pavlovich, J. Folkman, E. E. Voest, X. Chen, A. D. Luster, and M. A. O'Donnell. 1998. Intravesical bacille Calmette-Guérin induces the antiangiogenic chemokine interferon-inducible protein 10. Urology 52:268.
39. Patard, J. J., F. Saint, F. Velotti, C. C. Abbou, and D. K. Chopin. 1998. Immune response following intravesical bacillus Calmette-Guérin instillations in superficial bladder cancer: a review. Urol. Res. 26:155.
40. Flesch, I. E., J. H. Hess, S. Huang, M. Aguet, J. Rothe, H. Bluethmann, and S. H. Kaufmann. 1995. Early interleukin 12 production by macrophages in response to mycobacterial infection depends on interferon γ and tumor necrosis factor α. J. Exp. Med. 181:1615.
41. Troy, A. J., P. J. T. Davidson, C. H. Atkinson, and D. N. J. Hart. 1999. CD1a dendritic cells predominate in transitional cell carcinoma of bladder and kidney but are minimally activated. J. Urol. 161:1962.
42. Matsumoto, H., K. Suzuki, K. Tsuyuguchi, E. Tanaka, R. Amitani, A. Maeda, K. Yamamoto, M. Sasada, and F. Kuze. 1997. Interleukin-12 gene expression in human monocyte-derived macrophages stimulated with Mycobacterium bovis BCG: cytokine regulation and effect of NK cells. Infect. Immun. 65:4405.
43. Ye, J., J. R. Ortaldo, K. Conlon, R. Winkler-Pickett, and H. A. Young. 1995. Cellular and molecular mechanisms of 1FN-γ production induced by IL-2 and IL-12 in a human NK cell line. J. Leukocyte Biol. 58:225.
44. Luo, Y., X. Chen, T. M. Downs, W. C. DeWolf, and M. A. O'Donnell. 1999. IFN-α 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy. J. Immunol. 162:2399.
45. Okamura, H., H. Tsutsui, T. Komatsu, M. Yutsudo, A. Hakura, T. Tanimoto, K. Torigoe, T. Okura, Y. Nukada, K. Hattori, et al. 1995. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 378:88.
46. Ushio, S., M. Namba, T. Okura, K. Hatorri, Y. Nukada, K. Akita, F. Tanabe, K. Konishi, M. Micallef, M. Fujii, et al. 1996. Cloning of the cDNA for human IFN-γ inducing factor, expression in Escherichia coli and studies on the biological activities of the protein. J. Immunol. 156:4274.
47. Ahn, H.-J., S. Maruo, M. Tomura, J. Mu, T. Hamaoka, K. Nakanishi, S. Clark, M. Kurimoto, H. Okamura, and H. Fujiwara. 1997. A mechanism underlying synergy between IL-12 and IFN-γ-inducing factor in enhanced production of IFN-γ. J. Immunol. 159:2125.
48. Kohno, K., J. Kataoka, T. Ohtsuki, Y. Suemoto, I. Okamoto, M. Usui, M. Ikeda, and M. Kurimoto. 1997. IFN-γ-inducing factor (IGIF) is a costimulatory factor on the activation of Th1 but not Th2 cells and exerts its effect independently of IL-12. J. Immunol. 158:1541.
49. Takeda, K., H. Tsutsui, T. Yoshimoto, O. Adachi, N. Yoshida, T. Kishimoto, H. Kamura, K. Nakanishi, and S. Akira. 1998. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 8:383.
50. Jackson, A. M., A. V. Ivshina, O. Senko, A. Kuznetsova, A. Sundan, M. A. O'Donnell, S. Clinton, A. B. Alexandroff, P. J. Selby, K. James, et al. 1998. Prognosis of intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndrome analysis. J. Urol. 159:1054.